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Objectives. The proarrhythmic risk of class I antiarrhythmic
agents in combination with myocardial ischemia is mainly the
result of their effects on ventricular repolarization. This study was
designed to evaluate the effect of class Ic antiarrhythmic agents on
QT dispersion during myocardial ischemia.
Background. QT interval dispersion on the 12-lead electrocar-
diogram (ECG) has been suggested as a noninvasive marker of
inhomogeneous ventricular repolarization and susceptibility to
ventricular arrhythmias.
Methods. In a randomized, double-blind study, 98 patients
undergoing percutaneous transluminal coronary angioplasty
(PTCA) were pretreated with propafenone or placebo. QT disper-
sion was defined as a maximal minus minimal QT interval on the
12-lead ECG before and after PTCA. The power of the study to
detect clinically meaningful differences in QT dispersion was 0.75,
and a twofold increase in QT dispersion in the propafenone group
compared with the placebo group was considered clinically rele-
vant.
Results. The QT and corrected QT (QTc) intervals increased
significantly during occlusion of the left anterior descending
coronary artery (LAD) (9% and 11%, respectively, p < 0.05),
whereas occlusion of the circumflex and right coronary arteries
had no effect. QTc dispersion increased significantly in the
propafenone group during ischemia (152%, p 5 0.002, vs. 123%,
p 5 0.15). The most considerable effect on QT dispersion was
observed during LAD occlusion and ischemia of the anterior wall
(174%, p5 0.025). Corrected JT dispersion (157%, p5 0.017, vs.
124%, p 5 0.23) and the QT dispersion ratio (11.6%, p 5 0.031,
vs. 0.9%, p 5 0.34) showed similar effects. Plasma levels of
propafenone (522 6 165 mg/liter) did not influence the results.
Conclusions. During myocardial ischemia, particularly during
LAD occlusion, propafenone results in a significant increase in
QT dispersion. The results indicate that QT interval prolongation
and enhanced QT dispersion reflect inhomogeneous ventricular
repolarization generated by the ischemic anterior wall of the
myocardium. These observations may demonstrate a clinically
important interaction between myocardial ischemia, repolariza-
tion variables and propafenone.
(J Am Coll Cardiol 1997;29:561–7)
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Class I antiarrhythmic agents have been recognized as increas-
ing the risk of sudden cardiac death when used in patients with
coronary artery disease (1–4). More recently, increasing evi-
dence has stressed the interaction of myocardial ischemia and
class I antiarrhythmic activity (1,5–17) to explain the excess of
sudden cardiac death mortality in the treatment arm of the
Cardiac Arrhythmia Suppression Trial (CAST). This concept
was supported by a recent subgroup analysis in the CAST
population (18). However, very little is known of the beneficial
or hazardous effects of class Ic antiarrhythmic activity in
association with myocardial ischemia. Experimental data fo-
cusing on the conduction delay induced by both class Ic activity
and myocardial ischemia demonstrated significant proarrhyth-
mia due to a loss of antiarrhythmic efficacy and an increase in
the heterogeneity of the repolarization process (7).
QT interval dispersion has been suggested as a noninvasive
marker of such inhomogeneous ventricular repolarization (19–
21) and susceptibility to ventricular arrhythmias, as has been
shown in patients with the congenital long QT syndrome
(22–31). Studies on the diagnostic impact of this variables also
addressed patients with myocardial ischemia and infarction
and those receiving antiarrhythmic therapy (19–21,31). How-
ever data on the combination of both myocardial ischemia and
antiarrhythmic agents in patients are lacking.
In a prospective, double-blinded, randomized study, we
assessed the effect of acute myocardial ischemia on ventricular
repolarization dispersion (QT dispersion) on the surface elec-
trocardiogram (ECG) in 98 patients pretreated with either
placebo or propafenone while undergoing percutaneous trans-
luminal coronary angioplasty (PTCA).
Methods
Patients. Ninety-eight patients were consecutively included
in the study and randomized to receive either placebo (47
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patients) or propafenone (51 patients). There were 14 women
and 84 men, with a mean [6SD] age of 59 6 7 years (range 41
to 75). The study protocol was accepted by the local ethics
committee, and written informed consent was obtained from
all patients.
Patients were included in the study only when the following
criteria were met: coronary artery disease with one or more
stenotic lesion, lumen narrowing .75% and symptomatic and
exercise-inducible myocardial ischemia giving the clinical indi-
cation for PTCA. Exclusion criteria for the study were age.75
years old, complete coronary artery occlusion, pretreatment
with any antiarrhythmic agent, severe heart failure of New
York Heart Association functional class IV, severe liver and
kidney dysfunction, asthmatic disease, presence of atrial fibril-
lation, bundle branch block or first-degree or greater atrioven-
tricular block.
The clinical data of all patients entered into the study are
summarized in Table 1. No difference was seen between the
two treatment groups regarding clinical characteristics or the
presence, frequency and severity of myocardial ischemia be-
fore the study, severity of coronary stenotic lesions, exercise
tolerance, ejection fraction or presence of heart failure. Ejec-
tion fraction in all patients was .35%.
Study design. Before entering the study, all patients under-
went physical examination, chest radiography, echocardiogra-
phy, 24-h Holter monitoring, exercise testing and PTCA.
Twenty-four hour Holter monitoring and exercise testing were
performed in all patients in a parallel design on the day before
PTCA. Whenever possible, anti-ischemic medication (includ-
ing beta-adrenergic blocking agents) was stopped at least 5
drug half lives before PTCA, except for short-acting nitrates.
No further concomitant drug therapy was allowed during the
study.
After inclusion in the study, patients were randomized to
receive either placebo or propafenone. Both placebo and
propafenone were given intravenously, starting 60 min be-
fore the start of PTCA. Patients randomized to receive pro-
pafenone received a bolus of 70 mg over 10 min followed by a
maintenance infusion of 17.5 mg/h until the end of the PTCA.
All patients were pretreated with 15,000 IU of heparin before
PTCA. From blood samples that were obtained immediately
before the first balloon inflation, the plasma concentration of
propafenone was determined.
PTCA was performed in all patients by a standardized
protocol. Whenever possible, the balloon inflation time was
standardized to 60 s for the first attempt, 90 s for the second
attempt and 120 s for the third and all following attempts.
Simultaneous 12-lead surface ECGs were continuously re-
corded with a paper speed of 25 mm/s during the procedure
and 50 mm/s before and until 5 min after balloon inflation.
Time of onset and disappearance of symptoms of angina
pectoris was documented during each PTCA attempt.
Assessment of ECG measurements. Data analysis was
based on the first 60-s PTCA attempt. Data were obtained at
baseline, after bolus injection and every 30 s starting with the
onset of balloon inflation and ending 5 min after the onset of
reperfusion. Electrocardiographic assessment included PQ,
QRS, RR and QT intervals. Before and immediately after the
end of balloon inflation (maximal ischemia), the QT interval
and the interval between J point and the end of the T wave (JT
interval) were manually measured on each of the 12 standard
leads obtained with a recording speed of 50 mm/s. The
Abbreviations and Acronyms
CAST 5 Cardiac Arrhythmia Suppression Trial
ECG 5 electrocardiogram, electrocardiographic
JTc 5 corrected JT interval
LAD 5 left anterior descending coronary artery
PTCA 5 percutaneous transluminal coronary angioplasty
QTc 5 corrected QT interval
Table 1. Clinical and Angiographic Characteristics in the Two
Study Groups*
Propafenone
Group
(n 5 51)
Placebo
Group
(n 5 47)
Women/men 9/42 5/42
Age (yr) 59 6 7 57 6 8
History of infarction 30 (59%) 28 (60%)
Heart failure
NYHA class #I 89 (82%) 5 (11%)
NYHA class II/III 9 (18%) 7 (15%)
Ejection fraction (%) 66 6 15% 65 6 14%
Angina pectoris 32 (63%) 29 (62%)
Episodes/wk 8 6 13 6 6 6
At rest 17 (33%) 15 (32%)
Risk factors
Lipid disease 38 (75%) 28 (60%)
Smoking 32 (63%) 25 (53%)
Hypertensive disease 26 (51%) 23 (49%)
Family history 21 (41%) 23 (49%)
Adiposity 16 (31%) 7 (15%)
Diabetes mellitus 7 (14%) 6 (13%)
Coronary artery disease
One vessel 26 (51%) 30 (64%)
Two vessel 17 (33%) 15 (32%)
Three vessel 6 (12%) 4 (9%)
No. of dilated stenotic lesions
(1st PTCA)
55 55
LAD 24 (44%) 27 (49%)
Cx 10 (18%) 11 (20%)
RCA 13 (24%) 10 (18%)
Stenotic lesion (1st PTCA) 89 6 7% 89 6 9%
Total no. of PTCA attempts 137 135
Mean PTCA pressure (atm) 8.42 6 2.64 8.65 6 2.44
Residual stenosis 24 6 10% 25 6 11%
Plasma level of propafenone (mg/liter) 522 6 165
Range 223–896
*p 5 NS for all comparisons. Data presented are mean value 6 SD or
number (%) of patients, unless otherwise indicated. Cx 5 circumflex coronary
artery; LAD 5 left anterior descending coronary artery; NYHA 5 New York
Heart Association functional class; PTCA5 percutaneous transluminal coronary
angioplasty; RCA 5 right coronary artery.
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corrected QT (QTc) and JT (JTc) intervals were calculated
using the Bazett formula. The QT interval was measured from
the beginning of the QRS complex to the end of the T wave.
The end of the T wave was defined visually as the point where
the T wave returned to baseline. In case of a superimposed U
wave, the QT interval was measured to the nadir between the
T and U waves (32).
QT and QTc dispersion was defined as the difference
between the minimal and maximal values on any of the 12
leads and was calculated from three consecutive complexes in
all patients, except for one patient before and two patients
after balloon inflation who had frequent ventricular ectopic
activity, limiting QT measurement. The QT dispersion ratio,
defined as QT dispersion divided by cycle length and expressed
as a percentage, was also calculated at baseline and at the end
of PTCA. The QT dispersion ratio was assessed according to a
recently published report (19). ST segment changes as well as
supraventricular and ventricular arrhythmias were also docu-
mented during the procedure. The measurements were made
by two investigators (T.F., K.D.) who had no knowledge of the
medication given to the patients. Intraobserver and interob-
server variability and reproducibility of the QT measurements
were evaluated in 10% of the study cohort. The incidence of a
difference $15 ms was 3.9% and 5.1% of a total of 720
measurements considered for analysis during the study for
both intraobserver and interobserver variability, respectively.
The statistical power of the study to detect clinically meaning-
ful differences between both groups was calculated to be 0.75.
Statistical analysis. Results are expressed as mean value6
SD. Data were compared before and after balloon inflation
using a paired Student t test, two-way repeated measures
analysis of variance and Mann-Whitney, chi-square and Wil-
coxon tests where appropriate. A p value,0.05 was considered
statistically significant.
Results
Clinical characteristics, baseline coronary artery anatomy
and the results of therapeutic intervention were similar in the
placebo and propafenone groups (Table 1).
Symptoms of angina pectoris and myocardial ischemia
during coronary artery occlusion. Propafenone pretreatment
was associated with a significantly higher incidence and earlier
onset of symptoms of angina pectoris during acute coronary
artery occlusion (time to onset 25 6 20 s vs. 35 6 20 s) and a
significantly greater incidence, severity and duration of isch-
emic ST segment changes than placebo pretreatment when all
PTCA attempts were considered (Table 2).
The PQ interval increased significantly only in the
propafenone group (from 171 6 22 to 181 6 25 ms, p , 0.05)
during balloon inflation. Conversely, the RR interval changed
significantly in the placebo group (from 893 6 159 to 834 6
172 ms, p, 0.05) during transient coronary occlusion, whereas
it remained unchanged in the propafenone group. However,
PQ and RR intervals were not significantly different between
both groups before and after balloon inflation. Mean QRS
duration increased during acute ischemia slightly when the
patient was pretreated with propafenone (from 93 6 17 to
95 6 17 ms); however, the difference was not significant
compared with placebo pretreatment (from 94 6 11 to 91 6
12 ms, p , 0.05). Nevertheless, when a predefined increase in
QRS duration .20% was chosen, of seven patients (7%) who
met this criterion, six were in the propafenone group (mean
QRS duration 132 6 17 ms).
QT and QTc intervals and QT and QTc dispersion during
acute myocardial ischemia. In both groups, mean QT and
QTc intervals remained widely unchanged during coronary
artery occlusion in any single lead. However, in leads reflecting
the region of maximal ischemia, both mean QT and QTc
intervals increased significantly in 69% (propafenone group)
and 55% (placebo group) of patients during occlusion of the
left anterior descending coronary artery (QT interval 111%:
from 340 6 46 to 379 6 65 ms for propafenone vs. from 361 6
78 to 399 6 88 ms for placebo, p , 0.05; QTc interval 19%:
from 417 6 28 to 456 6 35 ms for propafenone vs. from 411 6
33 to 447 6 39 ms for placebo, p , 0.05). However, in both
treatment groups, lengthening of the QT and QTc intervals
was of similar degree even in more distant leads (19% vs.
18%, p, 0.05). In contrast, a slight, nonsignificant shortening
of the QT and QTc intervals during balloon inflation was
observed in only 30% of the placebo group and 12% of the
propafenone group. In both treatment groups, no significant
lengthening or shortening of the QT and QTc intervals oc-
curred during occlusion of the circumflex and right coronary
artery either in leads adjacent to the ischemic area or in more
distant leads. Thus, both QT and QTc intervals were affected
by the treated vessel rather than by lead selection and drug
pretreatment. The effects of acute ischemia and propafenone
on maximal and minimal QTc intervals are given in Figure 1.
In patients pretreated with propafenone, a slight increase in
Table 2. Mean Changes in Clinical and Electrocardiographic
Variables in Both Study Groups During Percutaneous Transluminal
Coronary Angioplasty
Propafenone
Group
Placebo
Group p Value
Incidence of angina pectoris
1st PTCA 26 (51%) 16 (34%) 0.650
All PTCA attempts 74 (54%) 59 (44%) 0.031
Incidence of ST segment depression
1st PTCA 21 (41%) 18 (38%) 0.710
All PTCA attempts 70 (51%) 60 (44%) 0.027
Maximal ST segment depression (mV)
1st PTCA 0.20 6 0.10 0.20 6 0.10 0.160
All PTCA attempts 0.27 6 0.26 0.18 6 0.09 0.028
Onset of ST segment depression (s)
1st PTCA 11 6 11 14 6 13 0.280
All PTCA attempts 17 6 9 21 6 12 0.015
Duration of ST segment depression (s)
1st PTCA 39 6 16 49 6 20 0.291
All PTCA attempts 68 6 24 51 6 17 0.024
Data presented are mean value 6 SD or number (%) of patients. PTCA 5
percutaneous transluminal coronary angioplasty.
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the minimal QT interval was contrasted by a significant
increase in the maximal QTc interval (p , 0.001) (Fig. 1). In
contrast, in the placebo group a moderate increase was ob-
served in both minimal and maximal QT intervals.
Results of the QTc dispersion analysis are summarized in
Table 3. Sixty seconds of acute coronary artery occlusion
resulted in a significant increase in the QTc dispersion time in
the propafenone group by 42% (p 5 0.02) compared to 114%
(p 5 0.76) in the placebo group. In both groups, the increase
in QT dispersion time was related to the severity of myocardial
ischemia; but in the presence of ST segment depression
$0.15 mV, the increase was 2.3 times greater in the
propafenone group (Table 3, Fig. 2). The most considerable
increase in QT dispersion was observed in the propafenone
group during occlusion of the LAD and ischemia of the
anterior wall (174%, from 35 6 32 to 61 6 27 ms, p 5 0.025)
compared with that in the placebo group (114%, from 436 17
to 49 6 18 ms, p 5 0.8). Compared with QTc dispersion time,
JTc dispersion time analysis showed similar results in the
propafenone (21 6 41 ms, 157%, p 5 0.017) and placebo
groups (10 6 39 ms, 124%, p 5 0.23). Without correction for
heart rate, a similar increase in QT dispersion of 138% (from
32 6 26 to 44 6 24 ms, p , 0.05) was observed in the
propafenone group during balloon inflation, whereas no sig-
nificant change occurred in the placebo group.
Of clinical variables analyzed, PTCA performed in the
presence of left ventricular hypertrophy at baseline was a risk
factor for an enhanced increase in the QTc dispersion time
response to myocardial ischemia in the propafenone group.
Presence and location of previous myocardial infarction had no
different effect on QTc dispersion time response in the
propafenone and placebo groups. However, patients with a
previous myocardial infarction showed a significantly greater
increase in QTc dispersion time during acute myocardial
ischemia, and the differences were greatest in patients with a
history of anterior versus inferior myocardial infarction (Table
3).
The mean plasma level of propafenone determined in blood
samples taken immediately before balloon inflation (82 6
Figure 1. Mean QTc dispersion (ms) and QT dispersion ratio (%) in
patients with myocardial ischemia treated with either propafenone or
placebo at baseline (open bars) and after 60 s of coronary occlusion
(solid bars). Only propafenone significantly increased QTc dispersion
and QT dispersion ratio.
Table 3. Mean Changes in Corrected QT Dispersion and QT Dispersion Ratio in Both Groups During Percutaneous Transluminal
Coronary Angioplasty
QTc Dispersion
Propafenone Group Placebo Group
Baseline
(ms)
End of
PTCA
(ms)
Mean QTd
Increase p Value
Baseline
(ms)
End of
PTCA
(ms)
Mean QTd
Increase p Value
LAD, RCA, Cx occlusion in all patients 386 28 54 6 26 142% 0.020 42 6 23 48 6 28 114% 0.76
p 5 0.022
LAD, RCA, Cx occlusion and ischemia* 406 27 59 6 26 152% 0.002 42 6 20 52 6 30 123% 0.15
p 5 0.048
LAD occlusion and ischemia* 356 32 61 6 27 174% 0.025 43 6 17 49 6 18 114% 0.80
p 5 0.032
LAD, RCA, Cx occlusion and hypertension 346 26 52 6 25 153% 0.025 41 6 23 49 6 34 120% 0.97
p 5 0.053
QT Dispersion Ratio
Propafenone Group Placebo Group
Baseline
End of
PTCA
Mean
QTr
Increase
p
Value Baseline
End of
PTCA
Mean
QTr
Increase
p
Value
All patients 3.9 6 2.9% 5.5 6 2.9% 11.6% 0.031 4.1 6 2.4% 5.0 6 3.5% 10.9% 0.340
(141%) (121%)
*ST segment depression,0.15 mV. Data presented are mean value6 SD, unless otherwise indicated. QTc5 corrected QT interval; QTd5QT interval dispersion;
QTr 5 QT dispersion ratio; other abbreviations as in Table 1.
? ?
? ?
? ?
? ?
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32 min after the first bolus injection of 70 mg) was
5226165 mg/liter (range 223 to 896). No statistically significant
relation was found between the plasma level of propafenone
and QT variables during myocardial ischemia. In particular, no
difference was observed between the propafenone plasma
concentration in patients with occlusion of the LAD and the
most pronounced changes in QT measures and those with
occlusion of the right and circumflex coronary arteries and
fewer changes in QT variables (528 6 161 vs. 512 6 175
mg/liter, respectively, p 5 0.27).
QT dispersion ratio increased when myocardial ischemia
was induced by PTCA in both study groups; however, the effect
was significantly greater in the propafenone group (141%, p5
0.031) than in the placebo group (121%, p5 0.34). In patients
without ischemic ST segment alteration, the QTc and JTc
dispersion times as well as the QT dispersion ratio remained
unchanged (Table 3, Fig. 2).
Ventricular tachyarrhythmias during coronary artery oc-
clusion. Before PTCA, 24-h Holter recording of the incidence
of ventricular arrhythmias (propafenone: 41 [80%] of 51
patients; placebo: 45 [96%] of 47 patients, p . 0.05), frequent
ventricular arrhythmias (.100/24 h) (propafenone: 11 patients
[22%], placebo: 11 patients [23%]) and ventricular pairs
(propafenone: 9 patients [18%], placebo: 9 patients [19%]) or
salvos/tachycardia (propafenone: 5 patients [10%], placebo: 1
patient [2%]) were similar in the two study groups.
During acute coronary artery occlusion, ventricular arrhyth-
mias were observed in 9 patients (18%) in the propafenone
group and 19 (38%, p, 0.05) in the placebo group. Repetitive,
nonsustained ventricular arrhythmias were observed in only
two patients in the placebo group. In no patient did sustained
tachyarrhythmias, including torsade de pointes arrhythmias,
occur during coronary occlusion.
Discussion
The use of antiarrhythmic drugs in patients with ventricular
tachyarrhythmias carries a 2% to 15% risk for clinically
manifest proarrhythmia (1,5,11). This risk seems particularly
high when class I antiarrhythmic agents are given to patients
with ischemic heart disease (2–4). In those patients, myocar-
dial ischemia itself is common and is already known to carry a
substantial risk for inducing or aggravating ventricular tachy-
arrhythmias (6,33). In addition, the interaction between myo-
cardial ischemia, ventricular arrhythmias and class I antiar-
rhythmic drugs has been proved in both experimental
(12,14,34–36) and clinical studies (8,10,37–42). Class Ic agents
have particularly been shown to slow ventricular impulse
propagation and to increase ischemia-induced nonuniform
ventricular repolarization (7), which is considered a potential
prerequisite for subsequent arrhythmic events (14,24).
QT dispersion. The clinical significance of QT interval
dispersion as a noninvasive variable for inhomogeneous ven-
tricular repolarization and predictor for ventricular arrhyth-
mias has been evaluated in both ischemic heart disease and
antiarrhythmic drug treatment (19–21,28,31,43,44). Several
studies demonstrated that an increased QT interval dispersion
after acute myocardial infarction (23,31,45) is predictive for
subsequent arrhythmic events during the follow-up period
(19). A close relation between administration of class I anti-
arrhythmic drugs, increased QT dispersion and subsequent
tachyarrhythmic events, mostly classified as torsade de pointes,
has also been shown even in the absence of myocardial
ischemia (20). Conversely, class III antiarrhythmic drugs, such
as amiodarone (20,46) and sotalol (26), had no negative effects
on, or even reduced, QT dispersion when studied in the same
patients.
The present study used a double-blind, placebo-controlled
design, and, to our knowledge, is the first to evaluate the effects
of myocardial ischemia on QT dispersion variables in a large
group of patients pretreated with a class Ic antiarrhythmic
agent. The power of the study to detect clinically meaningful
differences was 0.75, and a twofold increase in the difference of
QT dispersion in the propafenone group during PTCA com-
pared with the placebo group was considered clinically rele-
vant. The study showed that intravenous administration of
propafenone during acute coronary occlusion results in a
Figure 2. Maximal (solid lines) and minimal QTc
duration (open lines) in patients treated with either
propafenone or placebo at baseline and after 60 s
of myocardial ischemia. There was no difference in
minimal QTc duration, but a significant increase in
QTc maximal duration, in patients pretreated with
propafenone (p , 0.001).
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significant 2.5-fold increase in dispersion of QT/QTc and
JT/JTc measures over that with placebo administration.
As an important result, the study also showed that disper-
sion of QT/QTc and JT/JTc intervals in the propafenone group
was considerably higher with acute LAD occlusion and isch-
emic reaction of the anterior wall (174%, p 5 0.025) than
circumflex and right coronary artery occlusion. The effects on
dispersion variables were also found to be more pronounced
for a previous anterior wall infarction than for an inferior wall
infarction. Our results, which are consistent with others (45),
demonstrate the important influence of the site of coronary
occlusion on assessment of QT interval prolongation and QT
dispersion on the standard 12-lead ECG. The findings suggest
that measures of the ventricular repolarization process on the
12-lead ECG, as used in the present study, are mainly influ-
enced by ischemic changes in the anterior wall of the myocar-
dium, which is adjacent to the recording leads. In addition, the
greater ischemic zone commonly resulting from LAD occlu-
sion than from circumflex or right coronary artery occlusion
will further influence this factor. This observation may be of
particular significance for the methodologic approach when
assessing patients with coronary artery disease. The QT dis-
persion ratio (19), another repolarization variable, could not
be proved superior to the conventional method in assessing
repolarization abnormalities during acute myocardial isch-
emia.
QT interval and conduction. The negative effect of
propafenone on ventricular repolarization during myocardial
ischemia was not assessable by measuring the QT interval in
any single lead. However, a significant QT and QTc prolonga-
tion was observed in ;60% of patients when more than one
lead was considered. Mean QT/QTc prolongation was similar
in both leads reflecting the ischemic area and in more distant
leads and overall was most pronounced during occlusion of the
LAD. This finding suggests that the total amount of ischemic
myocardium contributes most to the repolarization pattern
assessed in any lead on the surface ECG (45).
When the shortest and longest mean QT intervals were
analyzed in the two study groups, there was only a slight
difference in minimal QTc interval in patients pretreated with
propafenone, whereas maximal QTc interval increased signif-
icantly when acute ischemia was induced. Thus, QTc/JTc
dispersion resulting from the combination of class I antiar-
rhythmic activity and acute ischemia was largely generated by
prolongation of the maximal QTc/JTc interval, an observation
that was also made in patients with unstable angina and acute
myocardial infarction with and without ventricular fibrillation
(19).
In six patients, all with a previous myocardial infarction, the
predefined criterion for QRS broadening of .20% of the
baseline value was observed when acute ischemia and
propafenone pretreatment were present. It is likely that the
observed increase in QRS duration reflects use-dependent
sodium channel blockade. However, because the increase in
QRS duration occurred during myocardial ischemia, the inter-
action of propafenone and myocardial ischemia must also be
considered an important factor for QRS prolongation, a
potential risk factor for facilitating nonuniform ventricular
recovery (1,18).
Despite the finding that the overall incidence of nonsus-
tained and sustained ventricular arrhythmias in both groups
was low or did not occur, singular ventricular ectopic beats
were less common in the propafenone group. Although this
may be partly due to the known antiarrhythmic properties of
propafenone, the CAST trial clearly demonstrated the adverse
and proarrhythmic effects of other class Ic agents (flecainide,
encainide) that have previously been shown to successfully
suppress ventricular arrhythmias (1,18). Thus, even if an
antiarrhythmic drug suppresses ventricular arrhythmias, it may
also exert proarrhythmic activity. In the present study, no
dangerous arrhythmias occurred in the propafenone group
during PTCA, although repolarization abnormalities increased
significantly. A longer duration of acute ischemia obviously
may have enhanced these effects and may have provoked
malignant arrhythmias. However, due to the ethical responsi-
bility of the investigators, this was not done. Although the
duration of myocardial ischemia in the present study was
relatively short, the model was nevertheless effective in dem-
onstrating a synergistic effect of acute ischemia and class I
antiarrhythmic activity on ventricular repolarization; thus, the
observations of the present study are of particular clinical
importance. Plasma concentrations of propafenone, deter-
mined immediately before balloon inflation, were found to be
in the therapeutic range, and no significant relation between
plasma levels and measurements of QT variables was observed.
This finding also confirms clinical findings that antiarrhythmic
and adverse effects of propafenone do not correlate adequately
with plasma concentrations. This lack of correlation has been
explained by the nonlinear dose–plasma concentration relation
of propafenone, predominantly in subjects with an extensive
metabolizer phenotype, due to its marked hepatic first-pass
metabolism through a saturable oxidative elimination pathway
(47,48).
Conclusions. To our knowledge, the present study is the
first to provide data on the effect of class Ic antiarrhythmic
agents in patients with ischemic episodes. A twofold increase in
the difference of QT dispersion in the study group during
coronary occlusion was considered clinically meaningful; thus,
the study demonstrated that in the setting of myocardial
ischemia, particularly in the anterior wall during LAD occlu-
sion, propafenone resulted in a significant increase in QT
interval dispersion, suggesting a nonuniform recovery of the
ventricle. The study further suggests that dispersion of QT
measures on the 12-lead ECG predominantly reflects abnor-
mal ventricular repolarization generated by ischemia in the
anterior wall of the myocardium, which may be of particular
importance for assessing patients with coronary artery disease.
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